Autor: |
Takafumi Nakayama, Junki Yamamoto, Toshikazu Ozeki, Yoshiro Tsuruta, Masashi Yokoi, Tomonori Aoi, Yoshiko Mori, Mayuko Hori, Makoto Tsujita, Yuichi Shirasawa, Chika Kondo, Kaoru Yasuda, Minako Murata, Yuko Kinoshita, Shigeru Suzuki, Michio Fukuda, Chikao Yamazaki, Noriyuki Ikehara, Makoto Sugiura, Toshihiko Goto, Hiroya Hashimoto, Kazuhiro Yajima, Shoichi Maruyama, Kunio Morozumi, Yoshihiro Seo |
Jazyk: |
angličtina |
Rok vydání: |
2023 |
Předmět: |
|
Zdroj: |
Biomedicines, Vol 11, Iss 2, p 592 (2023) |
Druh dokumentu: |
article |
ISSN: |
2227-9059 |
DOI: |
10.3390/biomedicines11020592 |
Popis: |
The clinical impact of ABO blood type on cardio-cerebrovascular outcomes in patients undergoing dialysis has not been clarified. A total of 365 hemodialysis patients participated in the current study. The primary endpoint was defined as a composite including cardio-cerebrovascular events and cardio-cerebrovascular death. The primary endpoint was observed in 73 patients during a median follow-up period of 1182 days, including 16/149 (11%) with blood type A, 22/81 (27%) with blood type B, 26/99 (26%) with blood type O, and 9/36 (25%) with blood type AB. At baseline, no difference was found in the echocardiographic parameters. Multivariable Cox regression analyses revealed that blood type (type A vs. non-A type; hazard ratio (HR): 0.46, 95% confidence interval (95% CI): 0.26–0.81, p = 0.007), age (per 10-year increase; HR: 1.47, 95% CI: 1.18–1.84), antiplatelet or anticoagulation therapy (HR: 1.91, 95% CI: 1.07–3.41), LVEF (per 10% increase; HR: 0.78, 95% CI: 0.63–0.96), and LV mass index (per 10 g/m2 increase; HR: 1.07, 95% CI: 1.01–1.13) were the independent determinants of the primary endpoint. Kaplan–Meier curves also showed a higher incidence of the primary endpoint in the non-A type than type A (Log-rank p = 0.001). Dialysis patients with blood type A developed cardio-cerebrovascular events more frequently than non-A type patients. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|